SRS16-86 (1793052-96-6) is a third generation ferrostatin derivative with greater metabolic and plasma stability for in vivo studies. It protected mice in a renal severe ischemia-reperfusion injury model via inhibition of ferroptosis.1 SRS16-86 enhanced functional recovery after spinal cord injury in a rat model via upregulation of GPX4, GSH, and xCT as well as downregulation of lipid peroxidation marker 4-hydroxynonenal.2
ChEBI: SRS16-86 is an ethyl ester resulting from the formal condensation of the carboxy group of 4-[(adamantan-1-yl)amino]-3-{(Z)-[(pyrimidin-5-yl)methylidene]amino}benzoic acid with tert-butanol. It is an inhibitor of ferroptosis induced by erastin in HT-1080 and NIH3T3 cells when used at a concentration of 1 muM. It has a role as a ferroptosis inhibitor. It is a tert-butyl ester, a member of adamantanes, a member of pyrimidines, a substituted aniline, a secondary amino compound and an imine.
Linkermann et al. (2014), Synchronized renal tubular cell death involves ferroptosis; Proc. Natl. Acad. Sci. USA. 111 16841
Zhang et al. (2019), Ferroptosis inhibitor SRS 16-86 attenuates ferroptosis and promotes functional recovery in contusion spinal cord injury; Brain Res. 1706 48
